You are here: silicon.com > Software > Security Strategy

Security Strategy

Round three for BT's Phorm trials

Ad-serving tech not so Ripa?

Tags: ripa, bt, phorm

By Tom Espiner

Published: 29 September 2008 15:41 GMT

BT is to perform another trial of Phorm's ad-serving technology, after delays of more than half a year.

Phorm's technology, which BT will use under the brand of 'Webwise', has attracted protests from peers, politicians, technologists and think tanks, who have expressed concerns over legal and privacy issues. The technology is also the subject of a probe by the European Commission.

Phorm's ad-serving technology works by assigning a user a unique identifier, through which the user's browsing habits are observed so as to target advertisements at them.

Security from A to Z

Click on the links below to find out more...

A is for Antivirus
B is for Botnets
C is for CMA
D is for DDoS
E is for Extradition
F is for Federated identity
G is for Google
H is for Hackers
I is for IM
J is for Jaschan (Sven)
K is for Kids
L is for Love Bug
M is for Microsoft
N is for Neologisms
O is for Orange
P is for Passwords
Q is for Questions
R is for Rootkits
S is for Spyware
T is for Two-factor authentication
U is for USB sticks/devices
V is for Virus variants
W is for Wi-fi
X is for OS X
Y is for You
Z is for Zero-day

BT will commence the third trial of the technology on Tuesday, a BT spokesperson said on Monday. "Around 10,000 customers will be invited to opt in to the trial when they commence their browsing session," said the spokesperson. "We will issue invitations at random."

The interstitial landing page will let customers accept or decline the invitation, or ask for more information about the trials, the spokesperson added.

BT announced a trial of Phorm's technology in April but then delayed the trial, apparently due to technical issues. The BT spokesperson declined to say what those issues had been.

The spokesperson added: "We can't go into the technical issues; they are confidential between us and Phorm. We're not going to be peering behind the curtain. You can assume, as we're going ahead with the trials, that we've resolved any outstanding issues to our entire satisfaction."

The spokesperson said BT had been exploring network-based ways to track anonymised users without having to use cookies but said this had not been the reason for the delay.

"In parallel, we have continued to explore network-based options," said the spokesperson. "The trial will not involve network-based options."

The trial will follow previous tests which took place in autumn 2006 and summer 2007. These earlier pilots caused an outcry among privacy campaigners, as they were conducted without gaining the consent of customers and without their knowledge. Phorm's opponents claimed the trials were illegal under the Regulation of Investigatory Powers Act (Ripa) and the Data Protection Act.

One opponent of the trial, the think tank Foundation for Information Policy Research (FIPR), still has legal concerns about the upcoming Phorm test. Richard Clayton, FIPR treasurer, told silicon.com sister site ZDNet.co.uk on Monday the organisation was concerned not only about the privacy implications but also about interception and copyright issues.

Clayton said: "We don't see how an opt-in system can work when one adult in a house can opt in on behalf of another adult or children in the house, or children can opt in on behalf of their parents. We're also surprised they are going ahead with the trials because of the interception element."

Clayton said that, to be legal under Ripa, both sides of the interception have to give their consent. As the other end of the interception would be search sites like Google or Yahoo!, or websites such as FIPR's, Clayton said he failed to see how consent could be gained by all parties.

"We haven't given permission for third parties to intercept the traffic from us to our viewers," said Clayton. "If not, then Ripa has been broken. There is also a whole pile of legal issues around interception and copyright and intellectual property, because we haven't waived the IP rights we have in our content."

However, Kent Ertugrul, chief executive of Phorm, told ZDNet.co.uk on Monday that he expected FIPR's legal concerns to be allayed.

Ertugrul said: "Over the course of several months, the people at FIPR have expressed concerns and virtually all of them have turned out to be unfounded. Over the past few months, a number of people have raised concerns and we have addressed every point that has been raised."

Ertugrul said Phorm has been working with the European Commission in its probe into the legality of Phorm's technology, and said he was confident the Commission would be satisfied.

He said: "There is a pattern that people become more confident through engagement with the technology, including the [Commission]. We're confident that people will not only tolerate it but welcome [Phorm] as a big step forward. The fact is [Phorm] is something that is being welcomed by all of the websites we've spoken with and with advertisers. Market research by ISPs suggests [Phorm] is welcomed by consumers."

  1. Zones
  2. Management
  3. Networks
  4. Software
  5. IT Services
  6. Hardware
  1. Verticals
  2. Public Sector
  3. Financial Services
  4. Retail & Leisure

Clive Longbottom Windows 7: Not perfect - but ready for prime time Microsoft's latest OS fixes most of Vista's ills - but still has challenges ahead

Stephen Kleynhans Mind the details with Windows 7 Just because it might work better than Vista, it doesn't mean you can be sloppy


  • Jobs
Clinical Research Physician, Manchester

Recruitment of volunteer patients -Ensure data quality in compliance with ICH-GCP guidelines -Act as key patient contact for the study -Act as a key ...

CDISC SAS programmer Clinical Trials

CDISC SAS programmer Clinical Trials Experienced 'Clinical Trial' SAS programmers are urgently required to join a market leading Clinical Research ...

Business Development Account Executive-Software Sales

FOLLOWING - 3+ years experience of selling to Pharmaceutical, Life Sciences or Bio Tech companies (Ideally to the Clinical trials areas within) - ...

Agenda Setters 2009
Welcome to the ninth annual Agenda Setters poll – silicon.com's list of the top 50 most influential individuals in the technology and IT industries, from techies and CIOs to entrepreneurs and business leaders. Find out more in our latest special report.





Quick Sitemap Links: